This article is more than 5 years old. Information may no longer be current.
Mitomycin can increase ostium size in dacryocystorhinostomy
Click Here to Manage Email Alerts
An intraoperative dose of mitomycin-C during dacryocystorhinostomy minimizes postoperative fibrosis, resulting in a larger postoperative ostium, according to a study.
Kasturi Bhattacharjee, FRCS(Ed), and colleagues at Gauhati Medical College and Hospital in India prospectively studied the use of mitomycin-C (MMC) during dacryocystorhinostomy (DCR) in 60 patients. The researchers evaluated two MMC concentrations applied intraoperatively — 0.4 mg/mL and 0.05 mg/mL. They compared the effects to a control group of patients not treated with MMC.
Half of patients in each group underwent single-flap DCR; the other half underwent a double-flap DCR technique, according to the study.
The researchers found that patients treated with 0.4 mg/mL of MMC had a significantly larger mean ostium compared to patients in the other two groups. Among patients treated with a single flap, the ostium averaged 16.6 mm² for 0.4 mg/mL MMC-treated patients vs. 4.8 mm² for 0.05 mg/mL MMC-treated patients and 3.6 mm² for control patients. Among patients treated with a double-flap procedure, the ostium averaged 17.5 mm² for 0.4 mg/mL MMC-treated patients vs. 4.9 mm² for 0.05 mg/mL MMC-treated patients and 4.5 mm² for control patients.
No significant difference was noted between the single- and double-flap groups, the authors noted.
The study is published in the August issue of Clinical & Experimental Ophthalmology.